

Special Issue

Diagnostic and Therapeutic Monitoring for Neurometabolic Disorders

Message from the Guest Editors

Neurometabolic disorders are a heterogeneous group of conditions that result in neurological disease sequelae, ranging from developmental delays to complex movement disorders and epilepsy. Diagnostic biomarkers are needed for many of these rare conditions, where clinical diagnosis may go unrecognized. Neurometabolic disorders are traditionally thought of as genetic conditions that result in the accumulation of abnormal metabolites which are often claimed to be neurotoxic. A growing number of therapeutic strategies have aimed to reduce these accumulating metabolites. Biomarkers which can augment genotype–phenotype correlations are critical to determine which patients benefit from treatment. Importantly, biomarkers associated with therapeutic monitoring are often lacking clinical trial endpoints. We welcome proposals on, but not limited to, the following topics:

- Targeted and untargeted metabolomics in neurometabolic disorders;
- Biomarker discovery and validation for the diagnosis of neurometabolic disorders;
- Genotype–phenotype correlations with biomarkers in patients with neurometabolic disorders;
- Therapeutic monitoring for patients with neurometabolic disorders.

Guest Editors

Dr. Curtis Coughlin


Center for Bioethics and Humanities, Department of Pediatrics,
University of Colorado Anschutz Medical Campus, Aurora, CO 80045,
USA

Dr. J.J.M. (Judith) Jans

Center for Molecular Medicine, University Medical Center Utrecht,
Utrecht, The Netherlands

Deadline for manuscript submissions

closed (15 December 2023)



Metabolites

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 6.9
Indexed in PubMed



mdpi.com/si/174921

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)





Metabolites

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 6.9
Indexed in PubMed



[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)



About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo

Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.4 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the first half of 2025).